Danone’s Nutricia unit has defeated a challenge by New Zealand’s dairy cooperative Fonterra to registration of an Australian patent for the use of a nutritional pill for increasing weight gain in frail, elderly people.
A judge overseeing a securities class action against former directors of failed pharmaceutical company QRxPharma and its legal advisor DibbsBarker has ruled that certain documents, including numerous emails sent by the law firm, are protected by attorney-client privilege.
The corporate regulator has launched civil proceedings against the former managing director of sandalwood oil producer Quintis, after the company kept its board in the dark about the termination of a supply contract with Nestle unit Galderma.
Generic pharmaceutical company Aspen Pharma has resolved a patent infringement case brought by the maker of the anti-depressant Lexapro, according to a Federal Court order Tuesday.
A judge has granted F. Hoffman La-Roche’s request for a temporary order blocking Sandoz from making or selling a biosimilar version of its patented biologic used to treat various cancers and rheumatoid arthritis.
GlaxoSmithKline is pushing for lower penalties in a case brought by the Australian Competition and Consumer Commission alleging the pharma giant breached the Australian Consumer Law in the marketing for its Voltaren Osteo Gel and Voltaren Emulgel pain relief products.
Three generic drug manufacturers cannot claim damages for an injunction barring the release of cheaper versions of Effexor-XR, even if the injunction was later overturned, pharmaceutical giant Wyeth told a judge on day two of a six-week trial over its blockbuster antidepressant.
The High Court has rejected a bid by biopharmaceutical company Samsung Bioepis Australia to challenge a ruling granting Pfizer preliminary discovery for a potential patent infringement case over autoimmune drug Enbrel.
Pharmaceutical giant Wyeth’s has launched an “ambush” at the beginning of a trial after a nine-year long battle against several generic drug makers, alleging infringement of a second patent for its blockbuster Effexor-XR, a judge heard Monday.
A decade-long courtroom battle over a patent for Effexor-XR that delayed the release of cheap versions of the anti-depressant is at the centre of a trial starting Monday in Sydney pitting four generic drug makers against pharmaceutical giant Wyeth.